Biolegend, 398602, Purified anti-human CD267 (TACI) Antibody, 100μg

TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, predominantly CD27+ memory B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs) and 1 potential N-linked glycosylation site in the extracellular domain. Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B. TACI also plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human TACI transfected cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality testedActivation, WB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications include: western blot5 and inducing of isotype switch signaling in B cells1, suppressing Ab production through TACI signaling2, inducing phosphorylation of PKA in B cells3.
Application References(PubMed link indicates BioLegend citation): Martinez-Gallo M, et al. 2013. J Allergy Clin Immunol. 131: 468-76. (Activation) Sakurai D, et al. 2007. Eur. J Immunol. 37: 110-8. (Activation) Sakurai D, et al. 2007. Blood. 109: 2961-7. (Activation) He B, et al. 2010. Nat. Immunol. 11: 836-45. (FC) Garcia-Carmona Y, et al. 2018. Front Immunol. 9: 2125. (WB)
RRID: AB_2820066 (BioLegend Cat. No. 398602)
Structure: A 32 kD type III transmembrane protein and belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI contains 2 cysteine-rich domains (CRDs) and 1 potential N-linked glycosylation site in the extracellular domain. Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing.
Distribution: Expressed on B cells, predominantly CD27+ memory B cells, and myeloma cells.
Function: Induces activation of the transcription factors NFAT, AP1, and NF-kB and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.
Cell Type: B cells
Biology Area: Immunology, Signal Transduction
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: Gross JA, et al. 2000. Nature 404:995. Wu Y, et al. 2000. J. Biol Chem. 275:35478. Yan M, et al. 2001. Nat. Immunol. 2:638. Hymowitz A, et al. 2005. J. Biol. Chem. 280:7218. Bischof D, et al. 2006. BLOOD. 107:3235.
Gene ID: 23495
UniProt: View information about CD267 on UniProt.org
Clone: 11H3
Regulatory Status: RUO
Other Names: TACI, TNFRSF13B
Isotype: Mouse IgG2a, κ